Results 151 to 160 of about 90,799,159 (308)

Interactive pathology teaching on Instagram: Engagement outcomes from a 4‐week pilot study

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Social media is increasingly employed for medical education, yet Instagram remains under‐explored for visually rich disciplines, such as pathology. Using an established Instagram profile (@Patholife, >6000 followers), we delivered a structured, interactive educational series covering colorectal cancer, melanoma, and prostate cancer over a 4 ...
Madison T. Hindes   +2 more
wiley   +1 more source

The UK Consumer's Attitudes to, and Willingness to Pay for, imported Foods [PDF]

open access: yes
We report results from an investigation into consumer preferences for locally produced foods. Using a choice experiment we estimate willingness to pay for foods of a designated origin together with certification for Organic and GM free status.
Arnoult, Matthieu H.   +2 more
core  

What is user engagement? revisited: A comprehensive review of the concept of user engagement from 2010 to 2025. An Annual Review of Information Science and Technology (ARIST) paper

open access: yesJournal of the Association for Information Science and Technology, EarlyView.
Abstract User engagement (UE) has long been proposed as a holistic framework for understanding user‐technology interactions and a mediator for outcomes of digital technology use, such as learning, health behavior change, information acquisition, and social connectivity.
Heather L. O'Brien
wiley   +1 more source

On the Use of Valuation Mechanisms to Measure Consumers' Willingness to Pay for Novel Products: A Comparison of Hypothetical and Non-Hypothetical Values [PDF]

open access: yes
Willingness to pay (WTP) estimates for novel products are needed to assess consumers' valuation of these products as well as for product adoption and optimal pricing strategies.
Silva, Andres   +3 more
core  

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Actual Media Reports on GM Foods and Chinese Consumers' Willingness to Pay for GM Soybean Oil [PDF]

open access: yes
Information has been proven to have significant impacts on consumers' behavior and willingness to pay (WTP). In this study, information on GM soybean oil is given in the form of real-life cases involving GM food.
Hu, Wuyang, Ding, Yulian, Zhong, Funing
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Estimating Consumer Willingness to Pay for Country-of-Origin Labeling [PDF]

open access: yes
Consumer willingness to pay for a mandatory country-of-origin labeling program is assessed. A consumer survey was conducted during 2002 in several grocery stores in Boulder, Denver, and Fort Collins, Colorado.
Loureiro, Maria L., Umberger, Wendy J.
core  

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Home - About - Disclaimer - Privacy